{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:37:19Z","timestamp":1779309439748,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.7759\/cureus.98208","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:01:48Z","timestamp":1764576108000},"source":"Crossref","is-referenced-by-count":1,"title":["Systematic Review and Meta-Analysis of the Incidence of Myocarditis and Guillain-Barr\u00e9 Syndrome in Adolescents Receiving COVID-19 mRNA Vaccine"],"prefix":"10.7759","author":[{"given":"Chakrapani","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhileshwar","family":".","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Kumar Neeraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saajid","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukalyan Saha","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anantsaznam","family":".","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080836","article-title":"Vaccine development against COVID-19: study from pre-clinical phases to clinical trials and global use","volume":"9","author":"Ahmed S","year":"2021","unstructured":"Ahmed S, Khan S, Imran I, et al.. Vaccine development against COVID-19: study from pre-clinical phases to clinical trials and global use. Vaccines (Basel). 2021, 9:10.3390\/vaccines9080836","journal-title":"Vaccines (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.6243","article-title":"Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis","volume":"177","author":"Watanabe A","year":"2023","unstructured":"Watanabe A, Kani R, Iwagami M, Takagi H, Yasuhara J, Kuno T. Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis. JAMA Pediatr. 2023, 177:384-94. 10.1001\/jamapediatrics.2022.6243","journal-title":"JAMA Pediatr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101180","article-title":"Vaccinating adolescents and children significantly reduces COVID-19 morbidity and mortality across all ages: a population-based modeling study using the UK as an example","volume":"9","author":"Shiri T","year":"2021","unstructured":"Shiri T, Evans M, Talarico CA, et al.. Vaccinating adolescents and children significantly reduces COVID-19 morbidity and mortality across all ages: a population-based modeling study using the UK as an example. Vaccines (Basel). 2021, 9:10.3390\/vaccines9101180","journal-title":"Vaccines (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.22037\/aaem.v10i1.1597","article-title":"Safety and adverse events related to COVID-19 mRNA vaccines; a systematic review","volume":"10","author":"SeyedAlinaghi S","year":"2022","unstructured":"SeyedAlinaghi S, Karimi A, Pashaei Z, et al.. Safety and adverse events related to COVID-19 mRNA vaccines; a systematic review. Arch Acad Emerg Med. 2022, 10:e41. 10.22037\/aaem.v10i1.1597","journal-title":"Arch Acad Emerg Med"},{"key":"ref5","unstructured":"Largest multi-country COVID study links vaccines to potential adverse effects. (2024). Accessed. 30 October 2025: https:\/\/www.news10.com\/news\/national\/largest-multi-country-covid-study-links-vaccines-to-potential-adverse-effects\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2669","article-title":"Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases","volume":"24","author":"Heidecker B","year":"2022","unstructured":"Heidecker B, Dagan N, Balicer R, et al.. Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2022, 24:2000-18. 10.1002\/ejhf.2669","journal-title":"Eur J Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4756","article-title":"COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect","volume":"9","author":"Matarneh AS","year":"2021","unstructured":"Matarneh AS, Al-Battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clin Case Rep. 2021, 9:e04756. 10.1002\/ccr3.4756","journal-title":"Clin Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100949","article-title":"mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study","volume":"40","author":"Soe P","year":"2024","unstructured":"Soe P, Vanderkooi OG, Sadarangani M, et al.. mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study. Lancet Reg Health Am. 2024, 40:100949. 10.1016\/j.lana.2024.100949","journal-title":"Lancet Reg Health Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.13.23299926","article-title":"Adverse events following SARS-CoV-2 mRNA vaccination in adolescents: a Norwegian nationwide register-based study","volume":"21","author":"Larsen VB","year":"2023","unstructured":"Larsen VB, Gunnes N, Gran JM, et al.. Adverse events following SARS-CoV-2 mRNA vaccination in adolescents: a Norwegian nationwide register-based study. medRxiv [PREPRINT]. 2023, 21:2023-12. 10.1101\/2023.12.13.23299926","journal-title":"medRxiv [PREPRINT]"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.6166","article-title":"Myocarditis or pericarditis events after BNT162b2 vaccination in individuals aged 12 to 17 years in Ontario, Canada","volume":"177","author":"Buchan SA","year":"2023","unstructured":"Buchan SA, Alley S, Seo CY, et al.. Myocarditis or pericarditis events after BNT162b2 vaccination in individuals aged 12 to 17 years in Ontario, Canada. JAMA Pediatr. 2023, 177:410-8. 10.1001\/jamapediatrics.2022.6166","journal-title":"JAMA Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004056","article-title":"Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: a multi-database, self-controlled case series study","volume":"19","author":"Massari M","year":"2022","unstructured":"Massari M, Spila Alegiani S, Morciano C, et al.. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: a multi-database, self-controlled case series study. PLoS Med. 2022, 19:e1004056. 10.1371\/journal.pmed.1004056","journal-title":"PLoS Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74729-2","article-title":"Global burden of vaccine-associated Guillain-Barr\u00e9 syndrome over 170 countries from 1967 to 2023","volume":"14","author":"Jeong YD","year":"2024","unstructured":"Jeong YD, Park S, Lee S, et al.. Global burden of vaccine-associated Guillain-Barr\u00e9 syndrome over 170 countries from 1967 to 2023. Sci Rep. 2024, 14:24561. 10.1038\/s41598-024-74729-2","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207847","article-title":"Risk of Guillain-Barr\u00e9 syndrome following COVID-19 vaccines: a nationwide self-controlled case series study","volume":"101","author":"Le Vu S","year":"2023","unstructured":"Le Vu S, Bertrand M, Botton J, et al.. Risk of Guillain-Barr\u00e9 syndrome following COVID-19 vaccines: a nationwide self-controlled case series study. Neurology. 2023, 101:e2094-102. 10.1212\/WNL.0000000000207847","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e76","article-title":"Adverse events following COVID-19 vaccination in adolescents: insights from pharmacovigilance study of VigiBase","volume":"39","author":"Kim DH","year":"2024","unstructured":"Kim DH, Kim JH, Oh IS, Choe YJ, Choe SA, Shin JY. Adverse events following COVID-19 vaccination in adolescents: insights from pharmacovigilance study of VigiBase. J Korean Med Sci. 2024, 39:e76. 10.3346\/jkms.2024.39.e76","journal-title":"J Korean Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.0583","article-title":"SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents","volume":"7","author":"Karlstad \u00d8","year":"2022","unstructured":"Karlstad \u00d8, Hovi P, Husby A, et al.. SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents. JAMA Cardiol. 2022, 7:600-12. 10.1001\/jamacardio.2022.0583","journal-title":"JAMA Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2023.01.016","article-title":"Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-a nationwide study","volume":"56","author":"Su WJ","year":"2023","unstructured":"Su WJ, Liu YL, Chang CH, et al.. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-a nationwide study. J Microbiol Immunol Infect. 2023, 56:558-65. 10.1016\/j.jmii.2023.01.016","journal-title":"J Microbiol Immunol Infect"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040749","article-title":"Myocarditis and pericarditis following COVID-19 vaccination in Thailand","volume":"11","author":"Mahasing C","year":"2023","unstructured":"Mahasing C, Doungngern P, Jaipong R, et al.. Myocarditis and pericarditis following COVID-19 vaccination in Thailand. Vaccines (Basel). 2023, 11:10.3390\/vaccines11040749","journal-title":"Vaccines (Basel)"},{"key":"ref18","unstructured":"Pfizer shares available analyses of myocarditis and COVID-19 vaccines. (2025). Accessed. 30 October 2025: https:\/\/www.pfizer.com\/news\/announcements\/pfizer-shares-available-analyses-myocarditis-and-covid-19-vaccines."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.951314","article-title":"Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis","volume":"9","author":"Voleti N","year":"2022","unstructured":"Voleti N, Reddy SP, Ssentongo P. Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:951314. 10.3389\/fcvm.2022.951314","journal-title":"Front Cardiovasc Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-025-01267-6","article-title":"Association between Guillain-Barr\u00e9 syndrome and SARS-CoV-2 virus infection, including the impact of COVID-19 vaccination in the context of the development and general clinical characteristics of the disease","volume":"31","author":"Sadowski J","year":"2025","unstructured":"Sadowski J, Huk J, Otulak S, et al.. Association between Guillain-Barr\u00e9 syndrome and SARS-CoV-2 virus infection, including the impact of COVID-19 vaccination in the context of the development and general clinical characteristics of the disease. J Neurovirol. 2025, 31:333-46. 10.1007\/s13365-025-01267-6","journal-title":"J Neurovirol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2022.2066522","article-title":"Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations","volume":"20","author":"Power JR","year":"2022","unstructured":"Power JR, Keyt LK, Adler ED. Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations. Expert Rev Cardiovasc Ther. 2022, 20:241-51. 10.1080\/14779072.2022.2066522","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1183258","article-title":"Guillain-Barr\u00e9 syndrome and COVID-19 vaccines: focus on adenoviral vectors","volume":"14","author":"Rzymski P","year":"2023","unstructured":"Rzymski P. Guillain-Barr\u00e9 syndrome and COVID-19 vaccines: focus on adenoviral vectors. Front Immunol. 2023, 14:1183258. 10.3389\/fimmu.2023.1183258","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437512-systematic-review-and-meta-analysis-of-the-incidence-of-myocarditis-and-guillain-barr-syndrome-in-adolescents-receiving-covid-19-mrna-vaccine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:01:49Z","timestamp":1764576109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437512-systematic-review-and-meta-analysis-of-the-incidence-of-myocarditis-and-guillain-barr-syndrome-in-adolescents-receiving-covid-19-mrna-vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.98208","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,30]]}}}